| HOME >> MEDICINE >> TECHNOLOGY |
Deals and alliances 27
Product deals 27
Technology deals 27
M&A activity 27
Company announcements 28
Future product milestones 29
Chapter 4 Company introduction 30
Key findings 30
Background 31
Key corporate developments 31
M&A history 32
Advanced Cardiovascular Systems acquired 32
Hybritech acquired 32
DowElanco formed 33
Devices for Vascular Intervention acquired 33
Origin Medsystems acquired 33
Sphinx Pharmaceuticals acquired 33
Guidant spun-out 33
Remaining medical device businesses divested 33
PCS Health Systems acquired 33
Hybritech divested 34
DowElanco holding sold 34
PCS Health Systems sold 34
Applied Molecular Evolution acquired 34
ICOS acquired 34
Hypnion acquired 34
Ivy Animal Health acquired 34
SGX Pharmaceuticals acquired 34
ImClone Systems acquired 35
M&A strategy 35
Current corporate structure 36
Pharmaceuticals 37
Elanco Animal Health 37
Pharmaceuticals business unit structure 38
Chapter 5 Company sales 39
Key findings 39
Prescription pharmaceutical sales and growth rate analysis, 2002-14 40
Product analysis 42
Product analysis, 2002-08 43
Product analysis, 2008-14 45
Therapy area analysis 49
Geographic analysis 53
Launch/core/expiry analysis 55
Explanation of launch/core/expiry analysis 55
Launch analysis, 2008-14 56
Core analysis, 2008-14 60
Expiry analysis, 2008-14 62
Launch/core/expiry configuration, 2008-14 64
Molecule type analysis 65
Externalization analysis 67
Chapter 6 Company financials 69
Key findings 69
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 70
Operating costs and pr
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |